Trial Profile
A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex ) associated to ZD6474 (Zactima) [vandetanib] or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 13 Jul 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 13 Jul 2011 Planned end date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 18 Apr 2011 Planned End Date changed from 1 Apr 2011 to 1 Jun 2011, according to ClinicalTrials.gov.